Peptide Hydrogel Combines Cancer Vaccine and CAR-T Cells in One System to Attack Solid Tumors

Researchers designed a self-assembling peptide that forms nanofiber scaffolds through non-covalent interactions of amphiphilic amino acids and ion stabilizers. Complementary peptide vaccine epitopes and CAR-T target sites were derived from different extracellular domains of HER2. The hydrogel was loaded with both the peptide epitope vaccine and CAR-T cells. In vitro experiments assessed CAR-T cell proliferation, cytotoxicity, and phenotype changes within the hydrogel. In vivo experiments in tumor-bearing mice evaluated anti-tumor efficacy, immune response induction (humoral and cellular), and central memory T cell generation in systemic immune tissues.

CAR-T therapy has transformed treatment for blood cancers like leukemia and lymphoma, but solid tumors represent over 90% of all cancers and remain largely resistant to CAR-T. The two biggest challenges — limited CAR-T persistence and the immunosuppressive tumor microenvironment — are both addressed by this peptide hydrogel system. By combining a vaccine that activates the body's own immune system with engineered CAR-T cells in a single sustained-release platform, this approach creates a more comprehensive and durable anti-tumor immune response.

This study represents the convergence of three major cancer immunotherapy strategies: CAR-T cell engineering, peptide-based cancer vaccines, and biomaterial-assisted immune modulation. Self-assembling peptide hydrogels are uniquely suited for this application because they are biocompatible, injectable, and can be precisely engineered to display specific epitopes. The concept of using a single biomaterial to coordinate both active (vaccine) and passive (CAR-T) immunity is novel and could transform how immunotherapy is delivered for solid tumors.

All experiments were conducted in mouse tumor models, which may not accurately predict human immune responses or solid tumor behavior. The HER2-specific system would only apply to HER2-positive cancers. Manufacturing complexity of combining a peptide hydrogel vaccine with live CAR-T cells presents significant clinical translation challenges. Long-term safety of sustained peptide hydrogel release at tumor sites is unknown. The immune response in immunodeficient tumor-bearing mice may differ substantially from immunocompetent cancer patients. Specific tumor sizes, survival curves, and quantitative immune metrics were not detailed in the abstract.